FDA-Approved Brain Tech Outsmarts Seizures

Technician reviews polygraph readings on a tablet beside a seated subject — Photo: Andrey Burmakin / Shutterstock

A brain implant that listens for seizures before they even start has now logged nine years of real-world results, and the seizure control keeps getting better over time, not worse.

Quick Take

Responsive Neurostimulation, or RNS, is an implanted device approved to treat adults with hard-to-control focal seizures.
Long-term data show seizure reduction climbing from 55% at three years to 75% at nine years.
RNS differs from Deep Brain Stimulation, or DBS, in where it sits and how it reacts to brain activity in real time.
Research comparing the two devices finds no clear winner, just two solid options for different patients.

Two Devices, One Goal: Stopping Seizures Before They Spread

RNS and DBS both treat epilepsy that medication cannot control. The difference comes down to timing and location. RNS sits directly on or near the spot in the brain causing seizures and watches brainwave activity around the clock. DBS, by contrast, delivers steady pulses to deeper brain structures on a set schedule, regardless of what the brain is doing moment to moment.

Mayo Clinic’s STEIN Fireside Podcast laid out this distinction for patients weighing surgical options. The discussion described how an epilepsy neurologist and a multidisciplinary team review each case, using tools like stereo-EEG and electrocorticography before recommending resection, laser ablation, or an implanted neurostimulator. That team-based approach reflects how major epilepsy centers already handle these decisions.

What the FDA Actually Approved, and Who Qualifies

The Food and Drug Administration (FDA) approved the RNS System in November 2013 for a specific group of adults. Patients must have partial-onset seizures coming from no more than two identified spots in the brain, frequent disabling episodes, and a history of failing at least two seizure medications first. This is not a treatment offered broadly; it targets people who have already tried standard drugs without success.

That narrow approval matters because it shapes who benefits most from the data that follows. The device is not marketed as a cure-all. It is built for a specific, well-defined population of drug-resistant focal epilepsy patients who have been through extensive testing to locate their seizure source first.

Nine Years of Data Show Results Improving Over Time

A prospective study following 256 patients for a median of nine years found seizure frequency dropped by a median of 75% at the nine-year mark, up from 55% at year three. Seventy-three percent of patients responded to treatment, and more than a third cut their seizures by at least 90%. Thirty percent had at least one stretch of six months or longer completely seizure-free.

These numbers come from real follow-up across multiple epilepsy centers, not isolated case reports. The research tracked nearly 1,900 combined years of patient experience with the implant. Cleveland Clinic researchers have pointed to this growing benefit over time as one of the more encouraging patterns in the epilepsy device field.

So Which Device Wins: RNS or DBS?

Despite strong interest in comparing the two, no large randomized trial has pitted RNS directly against DBS head-to-head. A 2024 systematic review pooling existing studies found seizure reduction of about 56% for DBS and 61% for RNS, a gap too small to call statistically significant. Responder rates landed close together too, at 67% for DBS and 71% for RNS.

A separate review from the International League Against Epilepsy’s Surgical Therapies Commission tracked RNS results climbing from 53% seizure reduction at two years to 66% at five years and 75% at nine years in open-label follow-up. The pattern across the research is consistent: both devices help a majority of patients, and neither has been proven broadly superior to the other.

What this means practically is that the choice between RNS and DBS depends on an individual patient’s seizure source, prior testing, and how well doctors can pinpoint where the seizures start. Patients whose seizures trace to one or two clear spots often fit the RNS profile best, while others may be better candidates for DBS or different surgical approaches entirely. That is exactly the kind of judgment call multidisciplinary epilepsy teams are built to make, and why patients benefit from centers that offer the full range of options rather than pushing one device as a default.